Chenodeoxycholic Acid Enhances the Effect of Sorafenib in Inhibiting HepG2 Cell Growth Through EGFR/Stat3 Pathway

BACKGROUND: Hepatocellular carcinoma (HCC) is a highly invasive disease with a high mortality rate. Our previous study found that Chenodeoxycholic acid (CDCA) as an endogenous metabolite can enhance the anti-tumor effect. Sorafenib has limited overall efficacy as a first-line agent in HCC, and combi...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yang, Zhang, Yan, Shi, Xiao-Jun, Li, Jun-Xiang, Wang, Lin-Heng, Xie, Chun-E, Wang, Yun-Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891169/
https://www.ncbi.nlm.nih.gov/pubmed/35252007
http://dx.doi.org/10.3389/fonc.2022.836333

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891169/
https://www.ncbi.nlm.nih.gov/pubmed/35252007
http://dx.doi.org/10.3389/fonc.2022.836333

Ejemplares similares